Value Partners Investments Inc. purchased a new stake in Stryker Corporation (NYSE:SYK – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,632 shares of the medical technology company’s stock, valued at approximately $1,002,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. AA Financial Advisors LLC boosted its holdings in Stryker by 9.0% in the third quarter. AA Financial Advisors LLC now owns 4,210 shares of the medical technology company’s stock valued at $1,159,000 after purchasing an additional 346 shares in the last quarter. Abel Hall LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at about $249,000. Richards Merrill & Peterson Inc. boosted its position in shares of Stryker by 1.3% in the 3rd quarter. Richards Merrill & Peterson Inc. now owns 18,581 shares of the medical technology company’s stock valued at $5,117,000 after purchasing an additional 230 shares during the period. Talbot Financial LLC grew its stake in Stryker by 22.7% during the 3rd quarter. Talbot Financial LLC now owns 71,125 shares of the medical technology company’s stock worth $19,587,000 after buying an additional 13,179 shares during the last quarter. Finally, Foguth Wealth Management LLC. grew its stake in Stryker by 3.9% during the 3rd quarter. Foguth Wealth Management LLC. now owns 1,357 shares of the medical technology company’s stock worth $400,000 after buying an additional 51 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.
Stryker Price Performance
Shares of NYSE SYK traded up $4.25 during trading on Monday, hitting $298.91. 3,064,306 shares of the company were exchanged, compared to its average volume of 2,453,146. The company has a market cap of $114.65 billion, a price-to-earnings ratio of 30.98, a PEG ratio of 1.87 and a beta of 0.78. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $392.55. The firm’s fifty day moving average price is $298.39 and its 200 day moving average price is $312.55. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.
Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the company posted $3.13 EPS. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts expect that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.
Stryker Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. Sanford C. Bernstein restated a “market perform” rating on shares of Stryker in a research report on Wednesday, October 7th. BTIG Research decreased their price objective on Stryker from $358.00 to $316.00 and set a “buy” rating for the company in a research report on Monday, October 12th. Wells Fargo & Company lowered their target price on Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $317.00 target price on shares of Stryker in a report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $369.00.
View Our Latest Stock Report on SYK
Insider Buying and Selling at Stryker
In other news, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 351,267 shares of company stock valued at $118,197,701. Corporate insiders own 4.60% of the company’s stock.
Stryker Profile
Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.
The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.
Featured Stories
- Five stocks we like better than Stryker
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
